|View printer-friendly version|
|Kindred Biosciences Announces Commercial Availability of Mirataz® (mirtazapine transdermal ointment) to Veterinarians in the United States|
Mirataz is the first and only transdermal medication for the management of weight loss in cats approved by the
"With approximately nine million cats experiencing unintended weight loss due to underlying conditions each year, we are very pleased to offer this first-in-class therapy to veterinarians," stated
To order Mirataz, veterinarians may contact their preferred animal health distributor, call 1-888-608-2542, or visit http://kindredbio.com.
Important Safety Information
Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves to apply and wash hands after. Avoid contact with treated cat for 2 hours following application. The most common adverse reactions include application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. Please see the full Prescribing Information.
For media inquiries:
View original content with multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-announces-commercial-availability-of-mirataz-mirtazapine-transdermal-ointment-to-veterinarians-in-the-united-states-300677202.html